Loading...
Loading...
BMEA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.1M |
| Gross Profit | -1.1M |
| Operating Expense | 27.7M |
| Operating I/L | -27.7M |
| Other Income/Expense | 2.8M |
| Interest Income | 2.8M |
| Pretax | -24.9M |
| Income Tax Expense | -0.4M |
| Net Income/Loss | -24.9M |
Biomea Fusion, Inc. is a biopharmaceutical company specializing in the development of covalent small molecule drugs for genetically defined cancers and metabolic diseases. Their lead product candidate, BMF-219, is an orally bioavailable, potent, and selective covalent inhibitor of menin, targeting oncogenic signaling in multiple cancers. The company generates revenue through the discovery, development, and potential commercialization of these innovative drugs, aiming to address unmet medical needs in the treatment of specific genetic conditions.
